Bio Fluid Sdn Bhd today signed a Memorandum of Agreement (MOA) with UiTM to further develop a new oral medication that will give hope to diabetic patients. Today’s historical session will kickstart an R&D project for the development of Ganoringa©, as oral antidiabetic medicine. This is part of UiTM’s effort through the Business Innovation & Technology Commercialization Center (BiTCOM) to accelerate the translation of important discoveries arising from research and innovation for the benefit of the country and the global community.
Today’s event was launched graced by Professor Datuk Ts. Dr Hajah Roziah Mohd Janor, UiTM’s Vice-Chancellor and BiTCOM director, Prof. Madya Ir. Ts. Dr. Syed Shatir Asghrar Syed Hassan. This collaboration will see commercialisation efforts between UiTM innovations and research products where the licensing agreement is valued at RM1,060,000.00. The collaborations will run from 3 – 5 years, with Bio Fluid’s project valued at RM 2,000,000.00, with the target to be in the market, both domestic and international, by end of 2022.
Since 2019, Bio Fluid has been making waves in the healthcare industry for its new and revolutionary “fluid” in nutraceutical technology and disinfectant products formulated with advanced nanotechnology commencing the use of Virgin Coconut Oil to derive its active component (Lauric Acid). Now eager to venture into pharmaceuticals, the team is honoured to collaborate with UiTM to develop a new formula from the polyherbal mixture of Moringa oleifera and Ganoderma lucidum (Ganoringa©).
The new drug developed has a high potential to be more effective than the standard drugs (insulin and metformin) in improving hyperglycaemia, hyperlipidemia without compromising tissues structure and function. Ganoringa© is also expected to boost the immunity of its consumer, thus impacting their quality of life to naturally maintain tissue homeostasis and repair damaged tissue.
“We would like to thank UiTM for their continued support of Bio Fluid. We have been successful through our first range of products formulated with Bio Extreem, which has been well accepted in the domestic and Middle East. Now venturing into pharmaceutical, the idea to further develop Ganoringa© was based on market demand, as Malaysia has the highest number of diabetics in Asia, and is the third country after Qatar and Guam. We are optimistic that the new drug will be a safe and effective holistic treatment for treating diabetic complications. Ganoringa© will also come along with
immune boosters and anti-aging properties,” said En. Rohaizad Abdul Raoof, Director & Co-founder of Bio Fluid Sdn Bhd, during a press conference today.
This statement was further supported by the Founder and Executive Chairman of Bio Fluid, YBhg Tan Sri Dr Mohd Daud Bakar, who continues to break barriers by tapping into the current demand due to the Covid-19 pandemic. During a short speech today, he further stated, “We hope to see more R&D projects continued by Malaysian researchers to be relevant to the current situation and focused on the studies of viruses. Whether common viruses or viruses that are sophisticated and mutated in society, Bio Fluid is focused on being in the forefront of developing highly effective products and a safer alternative to the health-conscious consumer.”
Bio Fluid is known for its cleaning and disinfectant products formulated with advanced nanotechnology using Virgin Coconut Oil to derive its active component (Lauric Acid). Their current products that are out in the market are as follows:
- Disinfectant Service using BF Plus + BF Control
- Surface sanitation service
- Nano spray therapeutic disinfectant soap (organic solution)
- Personal Care (Be Care Plus)
- Miraculous Face Mist & Device
- Decongestant Nasal Spray
- Instant Foaming Soap
More products will be developed within the health care and pharmaceuticals segment, including anti-inflammation spray, functional food, booster drink, and many more.
